BALPHARMA.BOBALPHARMA.BOBSE
Loading
Year-over-year earnings per share growth rate
3Y CAGR
-29.9%/yr
vs +161.2%/yr prior
Acceleration
-191.1pp
Decelerating
Percentile
P67
Within normal range
vs 3Y Ago
0.3x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 148.89% |
| Q3 2025 | 246.15% |
| Q2 2025 | -96.51% |
| Q1 2025 | 1030.30% |
| Q4 2024 | -49.23% |
| Q3 2024 | 306.25% |
| Q2 2024 | -95.38% |
| Q1 2024 | 517.86% |
| Q4 2023 | -6.67% |
| Q3 2023 | -21.05% |
| Q2 2023 | -25.49% |
| Q1 2023 | 161.54% |
| Q4 2022 | 432.06% |
| Q3 2022 | -61.42% |
| Q2 2022 | -87.33% |
| Q1 2022 | 368.75% |
| Q4 2021 | -67.01% |
| Q3 2021 | -9.35% |
| Q2 2021 | -56.85% |
| Q1 2021 | 785.71% |
| Q4 2020 | -6.67% |
| Q3 2020 | 0.00% |
| Q2 2020 | 110.45% |
| Q1 2020 | -9.54% |
| Q4 2019 | -87.14% |
| Q3 2019 | 19.08% |
| Q2 2019 | -183.17% |
| Q1 2019 | 85.71% |
| Q4 2018 | 311.32% |
| Q3 2018 | -147.32% |
| Q2 2018 | 566.67% |
| Q1 2018 | -172.73% |
| Q4 2017 | -26.67% |
| Q3 2017 | 200.00% |
| Q2 2017 | 27.42% |
| Q1 2017 | -244.19% |
| Q4 2016 | 258.33% |
| Q3 2016 | 200.00% |
| Q2 2016 | 101.97% |
| Q1 2016 | -233.55% |